Ligand id: 9421

Name: itolizumab

Immunopharmacology Comments
Itolizumab downregulates CD6-induced T-cell activation, inhibiting the synthesis of pro-inflammatory cytokines by T-helper (Th) 17 cells. However, the presence of CD6 on all T cells, and the lack of clarity around whether CD6 is a positive or negative co-stimulator of T-cell activation, warrants caution regarding the potentially widespread immunomodulatory effects of anti-CD6 therapy.
Immunopharmacology Disease
Disease X-Refs Comment References
Psoriasis Disease Ontology: DOID:8893
Approved drug for chronic plaque psoriasis.